Evotec is gearing up for ESCMID Global 2025 As a leader in infectious disease research, our team is driving innovation in antibacterial, antifungal, antituberculosis, and antiviral drug discovery. Visit us at Booth I40 to explore our cutting-edge platforms and discover how we can accelerate your projects. Join our poster presentations to gain insights into our latest advancements in anti-infective R&D. Don't miss this opportunity to connect with our experts and discuss groundbreaking solutions to create new therapeutics. See you in Vienna! Request a download of our scientific posters- https://hubs.ly/Q03cG-v_0 #ESCMID2025 #InfectiousDiseases #DrugDiscovery
About us
Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.
- Website
-
http://www.evotec.com
External link for Evotec
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Hamburg
- Type
- Public Company
- Specialties
- CNS, Oncology, Pain, Neurosciences, Inflammation, Metabolic disease, Infection, Respiratory diseases, Drug-Discovery, CMC, IND enabling, and Drug Development
Locations
-
Primary
Get directions
Manfred Eigen Campus
Essener Bogen 7
Hamburg, 22419, DE
Employees at Evotec
Updates
-
Only one week until our webinar on leveraging locked nucleic acid chemistry to enhance oligonucleotide characterization! Join us on 9 April to discover advanced pharmacokinetic models and screening strategies that optimize ASO design straight from industry experts. Register now to elevate your oligonucleotide drug discovery approach. https://hubs.ly/Q03f38LL0 #Oligonucleotides #Oligo #LNA #ASO #DrugDiscovery #ASOBasedDrugs #OligonucleotideTherapeutics
-
We feel honored to have been selected as a winner in the #biologics category of Outsourced Pharma’s CDMO Leadership Awards 2025. Jon Gunther, VP Business Development, took part in the celebration in New York and was thrilled to receive the award. A big thank you to our customers who made this win possible! Learn more about the event here- https://hubs.ly/Q03f2W-k0 #biotherapeutics #biomanufacturing
-
-
Exciting innovations are shaping the future of drug development, and Evotec's Carleen Kluger has shared her expertise in The Medicine Maker’s latest piece on next-generation sequencing (NGS) and multi-omics technologies in answer to this question "Looking ahead to the next 5–10 years, what will be the key disruptors and/or what can be improved upon in the pharma industry". In an era where precision medicine and data-driven insights are revolutionizing the industry, Carleen’s perspective highlights the critical role these technologies play in accelerating drug discovery and development. Read the full article here: https://hubs.ly/Q03f2-yd0 Let’s discuss—how do you see multi-omics shaping the future of medicine? Contact us at info@evotec.com #PanOmics #MultiOmics #NGS
-
-
Join the Evotec team at the 𝗖𝗲𝗹𝗹 & 𝗚𝗲𝗻𝗲 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗲𝗱 𝟮𝟬𝟮𝟱! We're looking forward to connect with industry leaders and innovators in the beautiful setting of Rome. Our SVP, Head of Cell Therapy Business Development, Bernd Muehlenweg, will be presenting 𝗘𝘃𝗼𝘁𝗲𝗰'𝘀 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝗶𝗲𝘀 𝗮𝗻𝗱 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘀𝗽𝗮𝗰𝗲 on Tuesday, 15 April at 5 PM CET. Additionally, we'll have a booth in the exhibit hall for more in-depth discussions. Don't miss this opportunity to discuss how Evotec can help you accelerate your cell therapy development. 𝗥𝗲𝗮𝗰𝗵 𝗼𝘂𝘁 𝘁𝗼 𝘀𝗰𝗵𝗲𝗱𝘂𝗹𝗲 𝗮 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝘂𝘀 𝗮𝗻𝗱 𝗹𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗯𝗼𝘂𝘁 𝗼𝘂𝗿 𝗽𝗿𝗲𝘀𝗲𝗻𝗰𝗲 𝗮𝘁 𝘁𝗵𝗲 𝗲𝘃𝗲𝗻𝘁 https://hubs.ly/Q03f4DQV0 #iPSC #Celltherapy #CGMed25 Irving Donadon, PhD, MBA; Bernd Muehlenweg; Silvia Aldi
-
-
In the complex world of drug discovery, 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗶𝗻𝘁𝗿𝗶𝗰𝗮𝘁𝗲 𝗯𝗶𝗼𝗰𝗵𝗲𝗺𝗶𝗰𝗮𝗹 𝗰𝗵𝗮𝗻𝗴𝗲𝘀 𝗶𝗻 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝘀𝘁𝗮𝘁𝗲𝘀 is critical. 𝗨𝗻𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰𝘀 is transforming our ability to 𝘂𝗻𝗰𝗼𝘃𝗲𝗿 𝗻𝗼𝘃𝗲𝗹 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀, 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺𝘀, 𝗮𝗻𝗱 𝗱𝗿𝘂𝗴 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲𝘀—without bias or predefined targets. But how does it work? And why is it a game-changer for biotech and pharma? Our latest blog, entitled 𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗣𝗼𝘄𝗲𝗿 𝗼𝗳 𝗨𝗻𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗠𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰𝘀 𝗶𝗻 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆, dives into: • How untargeted metabolomics accelerates drug discovery • Its impact on precision medicine and biomarker discovery • Why this approach is revolutionizing therapeutic innovation Read more and explore its potential- https://hubs.ly/Q03cGV2j0 #Metabolomics #Biomarkers #PrecisionMedicine
-
-
Unlocking Quality by Design: Quality Risk Management What are the key principles of Quality Risk Management (QRM) in drug product development? In the fourth episode of our "Mastering Quality by Design" webinar series, Simone Tescari will provide an overview of QRM philosophy aligned with ICHQ9 guidelines. How can effective risk management enhance your development cycle? https://hubs.ly/Q03c4tM80 Discover critical insights from our experts and watch the full "Mastering Quality by Design" series on demand!
-
-
Evotec reposted this
How can deeper insights into the immunological synapse accelerate immunotherapy discovery? Join our upcoming webinar, Driving Immunotherapy Discovery Through Analyzing the Immunological Synapse, to explore how advanced imaging and single-cell technologies are transforming immunotherapy research. Key Discussion Points: • Cutting-edge imaging techniques for visualizing T-cell interactions • The role of single-cell analysis in biomarker discovery • How these insights are shaping next-generation immunotherapies Gain expert perspectives on the latest innovations in immunology and drug development. Register now- https://hubs.ly/Q03chqvs0 #ImmunoTherapy #Immunology #Biomarker #Webinar
-
-
𝗘𝘃𝗼𝘁𝗲𝗰 𝗣𝗮𝗻𝗢𝗺𝗶𝗰𝘀: 𝗠𝗲𝗲𝘁 𝗛𝗮𝗻𝗻𝗮𝗵 𝗘𝗹𝗶𝘀𝗮 𝗞𝗿𝗮𝘄𝗰𝘇𝘆𝗸 We are proudly presenting a new video series, ‘Meet Our Computational Biology Experts’! Join us on our journey to meet the talented team and learn more about PanOmics, Evotec’s multi-omics supported drug discovery! Hannah Elisa is a research scientist at computational biology department at Evotec, responsible for analysis and interpretation of genetic and genomics data. Watch this introduction from Hannah Elisa to learn: • Why genetic and genomics data are important in drug discovery • How Evotec assesses genetic evidence to predict the efficacy and safety of drug targets • What can you do to raise probability of success Stay tuned as we share more insights, highlighting the inspiring research and the amazing work behind the scenes delivering cures to patients! #beCUREious Explore more on our website – https://hubs.ly/Q03cV1tT0 #beCUREious #ResearchNeverStops #Employee #LifeSciences #DrugDiscovery #MedicinesThatMatter #DataAnalytics #Bioinformatics #ComputationalBiology # PanHunter #MultiOmics #PanOmics #Genomics #Genetics #TargetId
-
Join us on 9 April, for a webinar on leveraging locked nucleic acid chemistry to enhance oligonucleotide characterization. Discover advanced pharmacokinetic models and screening strategies that optimize ASO design straight from industry experts. Register now to elevate your oligonucleotide drug discovery approach. https://hubs.ly/Q03dsj-W0 #Oligonucleotides #Oligo #LNA #ASO #DrugDiscovery #ASOBasedDrugs #OligonucleotideTherapeutics
-